文献速递白血病造血干细胞移植与细胞治疗

白血病中的PI3Kγ:IB类PI3激酶作为癌症内在靶点重新受到关注

PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
PubMed 文献 · Blood · 2025-01-01

本文综述了PI3Kγ作为白血病细胞内在靶点的最新研究进展。PI3Kγ抑制在实体瘤中通过重编程免疫抑制性髓系细胞发挥细胞外免疫治疗作用,而新近研究提出PI3Kγ在多种白血病尤其是急性髓系白血病中作为细胞内在靶点。部分白血病基线存在PI3Kγ内在依赖,另一些可由外部炎症诱导,并可能在某些治疗耐药后获得。

要点

  • PI3Kγ是唯一的IB类PI3激酶,在实体瘤中为细胞外免疫治疗靶点。
  • 新近研究提出PI3Kγ在多种白血病尤其急性髓系白血病中为细胞内在靶点。
  • 白血病对PI3Kγ的内在依赖可存在于基线、由炎症诱导或治疗耐药后获得。

核心结论

  • PI3Kγ作为白血病细胞内在靶点的发现激发了对抑制剂单药及联合方案立即开展临床试验评估的热情。
  • 需要平行开展实验室评估以更好理解与临床抑制剂敏感性相关的白血病疾病特征,从而提出生物标志物指导的患者富集策略。

研究设计与样本

  • 综述,讨论将PI3Kγ确认为白血病真正靶点的最新进展。

主要发现

  • PI3Kγ抑制在实体瘤中通过将免疫抑制性髓系细胞重编程为免疫刺激表型促进抗肿瘤细胞毒性T细胞活性。
  • PI3Kγ抑制对实体瘤细胞无直接作用,但新近多项研究提出PI3Kγ在多种白血病尤其急性髓系白血病中为细胞内在靶点。
  • 具有特定病理特征的白血病在基线即存在对PI3Kγ的内在依赖,其他白血病中可由外部炎症诱导,也可能在某些治疗耐药后获得。

局限性

  • 需要理解对PI3Kγ抑制获得性耐药的机制。
  • 需要明确如何最优优先选择联合治疗以增强PI3Kγ抑制剂的效用。
  • 需要了解白血病微环境中PI3Kγ抑制的细胞外效应如何也可能贡献临床活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phosphoinositide 3-kinase gamma (PI3Kγ), the only class IB PI3 kinase, is a cell-extrinsic immunotherapy target in solid tumors. PI3Kγ inhibition reprograms immunosuppressive myeloid cells to acquire immunostimulatory phenotypes, which promote antitumor cytotoxic T-cell activity. Although PI3Kγ inhibition has no direct effect on solid tumor cells, several new studies have nominated PI3Kγ as a cell-intrinsic target in various leukemias, particularly acute myeloid leukemia. Intrinsic dependency on PI3Kγ is present at baseline in leukemias with specific pathological characteristics, is inducible by extrinsic inflammation in others, and may also be acquired with resistance to certain therapies. The discovery of leukemia PI3Kγ dependency has generated enthusiasm for immediate clinical trial evaluation of inhibitor monotherapy and combinations. Parallel laboratory evaluation is needed to develop an improved understanding of leukemia disease features associated with clinical inhibitor sensitivity that might suggest biomarker-directed patient enrichment strategies. In this review, we discuss recent progress credentialing PI3Kγ as a bona fide target in leukemia. We also highlight open questions, including a need to understand the mechanism of acquired resistance to PI3Kγ inhibition, how to optimally prioritize combination therapies to enhance PI3Kγ inhibitor utility, and how cell-extrinsic effects of PI3Kγ inhibition in the leukemia microenvironment might also contribute to clinical activity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Luo Q, Fortune AL, Lane AA, et al. PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target. Blood. 2025. PMID: 40106765. doi:10.1182/blood.2024027376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。